• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S Common Stock (NY:NVO)

44.88 -1.01 (-2.20%)
Official Closing Price Updated: 6:30 PM EDT, Aug 17, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 14,620,637
Open 45.18
Bid (Size) 44.86 (900)
Ask (Size) 44.88 (2,000)
Prev. Close 45.89
Today's Range 44.68 - 45.45
52wk Range 35.12 - 64.16
Shares Outstanding N/A
Dividend Yield 5.68%
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
GLP-1 Demand Is Soaring. 2 Stocks That Could Benefit From This (Hint: Not Eli Lilly or Novo Nordisk) ↗
August 14, 2026
They are way more than just GLP-1 stocks. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Eli Lilly Just Scored Europe's First Weight Loss Pill Approval -- and the Growth Story Keeps Getting Bigger ↗
August 14, 2026
The U.K.'s health regulator just approved Eli Lilly's new weight-loss pill, a huge win for the drug maker. 
Via The Motley Fool

Performance

YTD
-14.3%
-14.3%
1 Month
-10.8%
-10.8%
3 Month
+1.4%
+1.4%
6 Month
-9.1%
-9.1%
1 Year
-16.5%
-16.5%

More News

Read More
News headline image
Eli Lilly's GLP-1 Pricing Problem Is Actually a Growth Opportunity ↗
August 13, 2026
Via The Motley Fool
News headline image
Is Novo Nordisk's Wegovy-Fueled Rebound Evaporating? ↗
August 13, 2026
Via The Motley Fool
News headline image
Hims & Hers’ Revenue Beat Came With a Profitability Problem ↗
August 12, 2026
Via MarketBeat
Topics Earnings Lawsuit
News headline image
Novo Nordisk Stock: Buy or Sell? ↗
August 11, 2026
Via The Motley Fool
News headline image
Better Buy: Eli Lilly vs. Novo Nordisk ↗
August 11, 2026
Via The Motley Fool
News headline image
Why Eli Lilly Topped the Market Today ↗
August 10, 2026
Via The Motley Fool
News headline image
Novo Nordisk A/S Q2 Earnings Call Highlights ↗
August 08, 2026
Via MarketBeat
Topics Earnings
News headline image
Eli Lilly's Timing of the FDA Filing of Its Next Weight-Loss Drug Is Now Official -- and Novo Nordisk Has a Problem ↗
August 07, 2026
Via The Motley Fool
News headline image
Pfizer's Next Weight-Loss Weapon: How Berobenatide Stacks Up Against Novo Nordisk's Wegovy and Eli Lilly's Zepbound ↗
August 07, 2026
Via The Motley Fool
News headline image
Why Is Everyone Talking About Novo Nordisk? ↗
August 06, 2026
Via The Motley Fool
News headline image
The FTC Is Suing Hims & Hers Health—Here's Why Investors Shouldn't Panic ↗
August 05, 2026
Via MarketBeat
Topics Lawsuit
News headline image
Bearish Pressure Is Building Around These 3 Stocks ↗
August 03, 2026
Via MarketBeat
Topics Artificial Intelligence
News headline image
Novo Nordisk Shares Plunge After a Key Trial Fails. Should Investors Buy the Dip? ↗
July 31, 2026
Via The Motley Fool
News headline image
Eli Lilly Stock Has Skyrocketed. Novo Nordisk Has Crashed. 1 Number Explains Why They're Not Even Close Anymore. ↗
July 31, 2026
Via The Motley Fool
News headline image
3 Beaten-Down Stocks With GLP-1 Exposure to Buy and Hold ↗
July 29, 2026
Via The Motley Fool
News headline image
Watch Out, Eli Lilly and Novo Nordisk: Amgen's Monthly Weight Loss Drug Has 6 Phase 3 Trials Running -- and It's Coming for Your Patients ↗
July 29, 2026
Via The Motley Fool
News headline image
Where Will Novo Nordisk Stock Be in 3 Years? ↗
July 28, 2026
Via The Motley Fool
News headline image
Why Is Novo Nordisk Suing Eli Lilly, and What Does it Mean for Investors? ↗
July 24, 2026
Via The Motley Fool
Topics Lawsuit
News headline image
2 Top Growth Stocks to Buy Right Now Without Any Hesitation ↗
July 24, 2026
Via The Motley Fool
News headline image
3 Absurdly Cheap Dividend Stocks to Buy With $1,000 Right Now ↗
July 23, 2026
Via The Motley Fool
Topics Lawsuit
News headline image
"Deceptive Advertising!" Claims Novo Nordisk in Explosive New GLP-1 Lawsuit Against Eli Lilly. Here's What That Means for Both Stocks. ↗
July 21, 2026
Via The Motley Fool
Topics Lawsuit
News headline image
Novo Nordisk's Dividend Story Is Changing -- Here's What Investors Are Missing ↗
July 21, 2026
Via The Motley Fool
News headline image
Next-Generation Diabetes Therapies Are Reshaping Healthcare and Creating MultiBillion-Dollar Revenue Opportunities
July 21, 2026
Via FinancialNewsMedia

Frequently Asked Questions

Is Novo Nordisk A/S Common Stock publicly traded?
Yes, Novo Nordisk A/S Common Stock is publicly traded.
What exchange does Novo Nordisk A/S Common Stock trade on?
Novo Nordisk A/S Common Stock trades on the New York Stock Exchange
What is the ticker symbol for Novo Nordisk A/S Common Stock?
The ticker symbol for Novo Nordisk A/S Common Stock is NVO on the New York Stock Exchange
What is the current price of Novo Nordisk A/S Common Stock?
The current price of Novo Nordisk A/S Common Stock is 44.88
When was Novo Nordisk A/S Common Stock last traded?
The last trade of Novo Nordisk A/S Common Stock was at 08/17/26 06:30 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap